Ensysce Biosciences Net Worth
Ensysce Biosciences Net Worth Breakdown | ENSC |
Ensysce Biosciences Net Worth Analysis
Ensysce Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Ensysce Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Ensysce Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Ensysce Biosciences' net worth analysis. One common approach is to calculate Ensysce Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Ensysce Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Ensysce Biosciences' net worth. This approach calculates the present value of Ensysce Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Ensysce Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Ensysce Biosciences' net worth. This involves comparing Ensysce Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Ensysce Biosciences' net worth relative to its peers.
To determine if Ensysce Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ensysce Biosciences' net worth research are outlined below:
Ensysce Biosciences generated a negative expected return over the last 90 days | |
Ensysce Biosciences has high historical volatility and very poor performance | |
Ensysce Biosciences has a very high chance of going through financial distress in the upcoming years | |
Ensysce Biosciences currently holds 854.7 K in liabilities with Debt to Equity (D/E) ratio of 6.91, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Ensysce Biosciences has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Ensysce Biosciences' use of debt, we should always consider it together with its cash and equity. | |
The entity reported the previous year's revenue of 2.23 M. Net Loss for the year was (10.63 M) with loss before overhead, payroll, taxes, and interest of (1.23 M). | |
Ensysce Biosciences currently holds about 3.15 M in cash with (10.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.1. | |
Ensysce Biosciences has a frail financial position based on the latest SEC disclosures | |
Latest headline from finance.yahoo.com: When Can We Expect A Profit From Ensysce Biosciences, Inc. |
Ensysce Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ensysce Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ensysce Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
4th of April 2024 Upcoming Quarterly Report | View | |
20th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
4th of April 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Ensysce Biosciences Target Price Consensus
Ensysce target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Ensysce Biosciences' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
One | Buy |
Most Ensysce analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Ensysce stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Ensysce Biosciences, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationEnsysce Biosciences Target Price Projection
Ensysce Biosciences' current and average target prices are 5.34 and 13.72, respectively. The current price of Ensysce Biosciences is the price at which Ensysce Biosciences is currently trading. On the other hand, Ensysce Biosciences' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Ensysce Biosciences Market Quote on 27th of February 2025
Target Price
Analyst Consensus On Ensysce Biosciences Target Price
Know Ensysce Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ensysce Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ensysce Biosciences backward and forwards among themselves. Ensysce Biosciences' institutional investor refers to the entity that pools money to purchase Ensysce Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | |||
Main Street Group Ltd | 2024-09-30 | 0.0 | |
Renaissance Technologies Corp | 2024-12-31 | 0.0 | |
Vanguard Group Inc | 2024-12-31 | 0.0 | |
Geode Capital Management, Llc | 2024-12-31 | 0.0 | |
Anson Funds Management Lp | 2024-12-31 | 0.0 | |
Virtu Financial Llc | 2024-09-30 | 0.0 | |
Xtx Topco Ltd | 2024-09-30 | 0.0 | |
Hrt Financial Llc | 2024-12-31 | 0.0 | |
Sabby Management Llc | 2024-09-30 | 1.2 M | |
Perceptive Advisors Llc | 2024-12-31 | 86.7 K | |
Adage Capital Partners Gp Llc | 2024-12-31 | 50 K |
Follow Ensysce Biosciences' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.03 M.Market Cap |
|
Project Ensysce Biosciences' profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (4.51) | (4.28) | |
Return On Capital Employed | 15.44 | 14.67 | |
Return On Assets | (4.51) | (4.28) | |
Return On Equity | 29.59 | 31.06 |
When accessing Ensysce Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Ensysce Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Ensysce Biosciences' profitability and make more informed investment decisions.
Please note, the presentation of Ensysce Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ensysce Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ensysce Biosciences' management manipulating its earnings.
Evaluate Ensysce Biosciences' management efficiency
Ensysce Biosciences has return on total asset (ROA) of (0.6258) % which means that it has lost $0.6258 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.049) %, meaning that it created substantial loss on money invested by shareholders. Ensysce Biosciences' management efficiency ratios could be used to measure how well Ensysce Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 31.06, whereas Return On Tangible Assets are projected to grow to (4.28). At present, Ensysce Biosciences' Other Current Assets are projected to increase significantly based on the last few years of reporting.Last Reported | Projected for Next Year | ||
Book Value Per Share | (0.33) | (0.31) | |
Tangible Book Value Per Share | (0.33) | (0.31) | |
Enterprise Value Over EBITDA | (3.00) | (3.15) | |
Price Book Value Ratio | (128.22) | (134.64) | |
Enterprise Value Multiple | (3.00) | (3.15) | |
Price Fair Value | (128.22) | (134.64) | |
Enterprise Value | 2.7 B | 2.4 B |
Leadership at Ensysce Biosciences emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ensysce Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ensysce Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ensysce Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ensysce Biosciences Corporate Filings
14th of February 2025 Other Reports | ViewVerify | |
8K | 4th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
19th of November 2024 Other Reports | ViewVerify | |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Ensysce Biosciences Earnings Estimation Breakdown
The calculation of Ensysce Biosciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Ensysce Biosciences is estimated to be -3.1125 with the future projection ranging from a low of -3.1125 to a high of -3.1125. Please be aware that this consensus of annual earnings estimates for Ensysce Biosciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-3.11 Lowest | Expected EPS | -3.11 Highest |
Ensysce Biosciences Earnings Projection Consensus
Suppose the current estimates of Ensysce Biosciences' value are higher than the current market price of the Ensysce Biosciences stock. In this case, investors may conclude that Ensysce Biosciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Ensysce Biosciences' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
0 | 21.2% | 0.07 | -3.1125 | -31.5 |
Ensysce Biosciences Earnings per Share Projection vs Actual
Actual Earning per Share of Ensysce Biosciences refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Ensysce Biosciences predict the company's earnings will be in the future. The higher the earnings per share of Ensysce Biosciences, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Ensysce Biosciences Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Ensysce Biosciences, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Ensysce Biosciences should always be considered in relation to other companies to make a more educated investment decision.Ensysce Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Ensysce Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-11-07 | 2024-09-30 | -0.29 | 0.07 | 0.36 | 124 | ||
2024-08-08 | 2024-06-30 | -0.39 | -0.22 | 0.17 | 43 | ||
2024-05-13 | 2024-03-31 | -0.9 | -0.55 | 0.35 | 38 | ||
2024-03-15 | 2023-12-31 | -0.87 | -1.37 | -0.5 | 57 | ||
2023-11-09 | 2023-09-30 | -1.06 | -0.87 | 0.19 | 17 | ||
2023-08-11 | 2023-06-30 | -2.73 | -0.98 | 1.75 | 64 | ||
2023-05-15 | 2023-03-31 | -5.08 | -2.08 | 3.0 | 59 | ||
2023-03-30 | 2022-12-31 | -28.88 | -18.24 | 10.64 | 36 | ||
2022-11-14 | 2022-09-30 | -3.2 | -0.74 | 2.46 | 76 | ||
2022-08-11 | 2022-06-30 | -3.4 | -4.8 | -1.4 | 41 | ||
2022-05-12 | 2022-03-31 | -3.2 | -1.2 | 2.0 | 62 | ||
2022-03-31 | 2021-12-31 | -0.4 | -9.0 | -8.6 | 2150 | ||
2021-11-15 | 2021-09-30 | -0.71 | -0.71 | 0.0 | 0 |
Ensysce Biosciences Corporate Management
MSE MBA | Chief Officer | Profile | |
Geoffrey Birkett | Chief Officer | Profile | |
Jeffrey Millard | Chief Officer | Profile | |
Linda Pestano | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ensysce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ensysce Biosciences. If investors know Ensysce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ensysce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (31.50) | Revenue Per Share | Quarterly Revenue Growth 6.853 | Return On Assets | Return On Equity |
The market value of Ensysce Biosciences is measured differently than its book value, which is the value of Ensysce that is recorded on the company's balance sheet. Investors also form their own opinion of Ensysce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ensysce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ensysce Biosciences' market value can be influenced by many factors that don't directly affect Ensysce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ensysce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ensysce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ensysce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.